Antibody-Drug Conjugates – Page 6

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

2 years ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

2 years ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)

Day One Biopharma Expands Pipeline with $55 Million Acquisition of MabCare’s Phase 1-Ready ADC

2 years ago talkbio0Tagged Acquisition (action), Antibody-Drug Conjugates, Biopharma, biotech, Daily, expansion, MabCare, Malignant Neoplasms, pipeline, PTK7 protein, human

Day One Biopharma, MabCare, Antibody Drug Conjugate (ADC), PTK7, Cancer Treatment, Biotech Acquisition, Pipeline Expansion

AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success

2 years ago talkbio0Tagged AbbVie, Antibody-Drug Conjugates, Antigens, Elahere, ovarian neoplasm, Phase 2 Clinical Trials, Return on Investment, ROI

AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere

AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment

2 years ago talkbio0Tagged AbbVie, Acquisition (action), Antibody-Drug Conjugates, Antigens, Clinical Trials, Elahere, Neoplasms, ovarian neoplasm

AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology

GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment

2 years ago talkbio0Tagged Antibody-Drug Conjugates, ASCO, Blenrep, CAR-T, Darzalex, DREAMM-7, DREAMM-8, Multiple Myeloma, Pomalyst, SmithKline Beecham, Velcade

Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate

AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment

2 years ago talkbio0Tagged Antibody-Drug Conjugates, ASCO, AstraZeneca, Carcinoma breast stage IV, Daiichi, Deruxtecan, Enhertu, Malignant neoplasm of breast, Sankyo, trastuzumab

Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment

Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer

2 years ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Clinical Trials, Gilead Sciences, Neoplasms, Overall Survival, Trodelvy, TROPiCS-04 study, United States Food and Drug Administration, urothelial cancer

Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval

BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront

2 years ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, biotech, China, Collaboration, Germany, MediLink, Solid Neoplasm, Technology Platform, TMALIN

BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany

Pheon Secures $120 Million in Series B Funding to Revolutionize Treatment for Challenging Cancers with Advanced Antibody-Drug Conjugates

2 years ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, hard-to-treat cancers, healthcare innovation, Pheon, Series B

Pheon, Series B funding, $120 million, hard-to-treat cancers, antibody-drug conjugates (ADCs), cancer treatment, biotechnology, healthcare innovation.